Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Shenzhen Stock Exchange  >  Hangzhou Tigermed Consulting Co.,Ltd    300347   CNE100001KV8

HANGZHOU TIGERMED CONSULTING CO.,LTD

(300347)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
04/07/2021 04/08/2021 04/09/2021 04/12/2021 04/13/2021 Date
145.3 146.5 141.85 136.03 136.33 Last
6478038 5733362 6323680 6669280 5692240 Volume
-0.49% +0.83% -3.17% -4.10% +0.22% Change
Financials
Sales 2021 4 127 M 631 M 631 M
Net income 2021 1 610 M 246 M 246 M
Net cash position 2021 10 563 M 1 615 M 1 615 M
P/E ratio 2021 73,2x
Yield 2021 0,28%
Sales 2022 5 444 M 833 M 833 M
Net income 2022 2 021 M 309 M 309 M
Net cash position 2022 11 326 M 1 732 M 1 732 M
P/E ratio 2022 58,5x
Yield 2022 0,39%
Capitalization 116 B 17 801 M 17 811 M
EV / Sales 2021 25,7x
EV / Sales 2022 19,3x
Nbr of Employees -
Free-Float 100,0%
More Financials
Company
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows: - provision of clinical trial services and related technological services (51.8%); - provision of clinical research consulting services (48.2%). 
More about the company
Notations Surperformance© of Hangzhou Tigermed Consulting Co.,Ltd
Trading Rating : Investor Rating :
More Ratings
All news about HANGZHOU TIGERMED CONSULTING CO.,LTD
03/29HANGZHOU TIGERMED CONSULTING  : (1) proposed partial repurchase and cancellation..
PU
03/26HANGZHOU TIGERMED CONSULTING  : Poll voting results of the 2021 second extraordi..
PU
03/10HANGZHOU TIGERMED CONSULTING  : Shareholders to Vote on DreamCIS Stock Option Bi..
MT
03/10HANGZHOU TIGERMED CONSULTING  : Notification Letter and Request Form to Non-Regi..
PU
03/10HANGZHOU TIGERMED CONSULTING  : Form of proxy for the 2021 Second Extraordinary ..
PU
03/10HANGZHOU TIGERMED CONSULTING  : Notice of the 2021 second extraordinary general ..
PU
03/10HANGZHOU TIGERMED CONSULTING  : Proposed adoption of the subsidiary share option..
PU
03/09HANGZHOU TIGERMED CONSULTING  : Announcement - book closure period for 2021 seco..
PU
01/28HANGZHOU TIGERMED CONSULTING  : Expects 2020 Profit to More Than Double; Shares ..
MT
2020HANGZHOU TIGERMED CONSULTING  : Full exercise of the over-allotment option, stab..
PU
2020HANGZHOU TIGERMED CONSULTING  : (1) proposed partial repurchase and cancellation..
PU
2020HANGZHOU TIGERMED CONSULTING  : 2019 Sustainability Report
PU
2020HANGZHOU TIGERMED CONSULTING  : Terms of reference for the strategy development ..
PU
2020HANGZHOU TIGERMED CONSULTING  : Terms of reference of the nomination committee o..
PU
2020HANGZHOU TIGERMED CONSULTING  : Terms of reference of the remuneration and evalu..
PU
More news
News in other languages on HANGZHOU TIGERMED CONSULTING CO.,LTD

- No features available -

More news
Chart HANGZHOU TIGERMED CONSULTING CO.,LTD
Duration : Period :
Hangzhou Tigermed Consulting Co.,Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HANGZHOU TIGERMED CONSULTING CO.,LTD
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Average target price 177,30 CNY
Last Close Price 136,33 CNY
Spread / Highest target 67,2%
Spread / Average Target 30,1%
Spread / Lowest Target -5,54%
EPS Revisions
Managers and Directors
NameTitle
Xiao Ping Ye Chairman & General Manager
Jun Gao Chief Financial Officer & Senior Vice President
Xiao Li Shi Chairman-Supervisory Board
Bi Yun Zheng Independent Director
Su Zeng Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
HANGZHOU TIGERMED CONSULTING CO.,LTD-15.64%17 801
MODERNA, INC.33.44%55 833
LONZA GROUP AG-5.70%43 206
IQVIA HOLDINGS INC.15.81%39 822
CELLTRION, INC.-11.98%37 710
SEAGEN INC.-19.56%25 513